SynopsisThe FDA defines remote clinical trials as those executed through telemedicine and mobile/local healthcare providers, using processes and technologies that differ from the traditional clinical trial model. The global Remote Clinical Trials market was valu.....
Synopsis Wellness describes itself as complete physical mental and social well-being. The global Healthcare and Wellness market was valued at US$ 5243 million in 2023 and is anticipated to reach US$ 8419.1 million by 2030, witnessing a CAGR of .....
SynopsisEYLEA® (aflibercept) Injection 2 mg (0.05mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD). The global Eylea market was valued at US$ 5617 million in 2023 and is anticipated to reach US$.....
SynopsisAflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. The global Aflibercept Drug market was valued at US$ 5617 million in 2023 and is anticipated to reach US$ .....
SynopsisArcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis. The global Arcalys.....
SynopsisRilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent .....
SynopsisEnbrel is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. The global Enbrel market was valued at US$ 8764 million in 2023 and is anticipate.....
SynopsisEtanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. The global Etanercept Drugs m.....
SynopsisALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. The global Alprolix market was valued at US$ 897 million in 2023 and is anticipate.....
SynopsisElocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). The global Elocta and Eloctate market was valued at US$ 1420 million in 2023 and is anticipated to reac.....
